[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]


Jo Anne;  Welcome to our wonderful forum, I am a five year breast cancer
survivor and was on the drug Tamoxifen for approximately six months.  Please
know we are pleased you are doing so well as a breast cancer survivor; but
concerned about your side effects to tamoxifen.  There are two other drugs
that work equally as well as tamoxifen; with few side effects; however most
drugs have some sort of side effect or another.  The secret is to use the
drug with the less serious of side effects and fewer.  The drugs are :
Megrace and Arimidex.

I am including information of side effects that some of us on the forum have
been working on.  Hope this is of help to you.  Stay and chat with us,
warmly, your friend, lillian

(Excerpt From Cancer & Hormone Paper)

Tamoxifen has been formally declared by the World Health Organization as a
carcinogen.  Under State Proposition 65, California must publish and
maintain a list of all known carcinogens.  In 1995, the state's Carcinogen
Identification Committee voted unanimously to list tamoxifen.  Tamoxifen's
known side effects include:

Liver Damage :    Britain withdrew from studies on the use of tamoxifen when
it was discovered that tamoxifen's manufacturer withheld unpublished data
indicating that the drug may induce liver tumors. Liver damage has occurred
in every animal study using tamoxifen.  Animal studies show tamoxifen
produces potentially carcinogenic DNA and alterations in the liver, as well
as eye damage.
Uterine Cancer :    Although the drug has had some success in preventing
recurrences in women who have been successfully treated for breast cancer,
it does promote particularly aggressive uterine cancer. A large Swedish
study, and another in the Netherlands, found a 6-fold increase in uterine
cancer among those patients who took tamoxifen.  In a University of
Pittsburgh study, 23 out of 1,000 given the drug, contracted uterine cancer.
Endometrial Effects :   A Danish/British study detected endometrial
abnormalities.  Uterine tumors, endometrial thickenings, and cancers
occurred in a significant number of women taking tamoxifen.
Blood Clots :   It is also known to cause fatal blood clots in the lungs,
irritating the walls of the veins, and leading to inflammation.
Osteoporosis :   Taxmoxifen users are at risk of developing early symptoms
of menopause, including accelerated bone mineral loss and osteoporosis.

Other adverse reactions which are seen infrequently are hypercalcemia,
peripheral edema, distaste for food, pruritus vulvae (vaginal itching),
depression, dizziness, light-headedness, headache, hair thinning and/or
partial hair loss, and vaginal dryness.

NOLVADEX has been associated with changes in liver enzyme levels, and on
rare occasions, a spectrum of more severe liver abnormalities including
fatty liver, cholestasis, hepatitis and hepatic necrosis.

Tamoxifen: A Major Medical Mistake?

                             by Sherrill Sellman

       Extracted from Nexus Magazine, Volume 5, #4 (June - July 1998)

     Once praised for its benefits in preventing breast cancer
     recurrence, the lucrative pharmaceutical drug tamoxifen is now
     implicated in causing dangerous side-effects, including other
     types of cancers.

     In the early 1970's, a shameful chapter closed on the widespread
     use of a known carcinogenic and endocrine-disrupting drug called
     DES (diethylstilboestrol), the first synthetic, non-steroidal
     estrogen drug. Against the advice of its creator, Sir Charles
     Dodd, between four and six million American and European women and
     10,000 Australian women innocently used DES for the prevention of
     miscarriage and pregnancy complications.

     In addition, DES became a popular though unproven drug for a
     variety of other conditions. It was used for the suppression of
     lactation, the treatment of acne, the treatment of certain types
     of breast and prostatic cancer, and as an inhibitor of growth in
     young girls, an estrogen replacement in menopause and a "morning
     after" pill.

     It would take 30 years to accept what laboratory tests had
     indicated as early as 1938 - that DES was a highly dangerous and
     harmful drug. It was reported that, 20 years after taking DES,
     mothers had a 40 to 50 per cent greater risk of breast cancer than
     non-exposed mothers. In addition, the children of DES mothers
     showed a high incidence of reproductive abnormalities,
     miscarriages, vaginal cancer, testicular cancer, sterility and
     immune dysfunction. In fact, it is feared that repercussions of
     this drug will be felt for generations to come.

     The irony of this entire debacle is that the medical establishment
     finally acknowledged that DES was useless in preventing
     miscarriages. Thus, DES, another disastrous experiment on women,
     was added to the long list of major medical blunders.

     Out of this early research, a new drug appeared on the horizon
     which would be soon be heralded as a shining star in the war
     against the growing epidemic of breast cancer. In the late 1960's
     the pharmaceutical industry developed a drug called "tamoxifen".
     As a synthetic, non-steroidal compound with hormone-like effects
     (many of which are poorly understood), tamoxifen has a similar
     structure to DES. In fact, it was observed that tamoxifen caused
     the same abnormal changes seen in cells of women taking estradiol
     and DES. (1) This similarity raised alarm bells for some.

     Pierre Blais, well known as a drug researcher who was ejected from
     Canada's health protection bureaucracy when he spoke out about
     silicone breast implants, describes the story of tamoxifen as "the
     story of modern drug design which produces garbage drugs". He
     says, "Good drug design ceased, unfortunately, in the 1930s."
     Tamoxifen, Blais asserts, " a garbage drug that made it to
     the top of the scrap heap. It is a DES in the making." (2)

     Blais's dire predictions were ignored with the promise of a
     potential drug treatment for breast cancer. Tamoxifen was first
     approved by the US Food and Drug Administration (FDA) for use as a
     birth-control pill; however, it proved to induce rather than
     inhibit ovulation. Although tamoxifen didn't work as a
     contraceptive, it was found to lower mammary cancer rates in
     animals. Animal studies showed that tamoxifen prevented estrogen
     from binding to receptor sites on breast tissue cells. Tamoxifen
     also reduced the incidence of breast cancer in rodents after
     administration of a breast-carcinogenic substance. This discovery
     provided the impetus to study its effects in treating human breast

     Estrogen is the common link between most breast cancer risk
     factors, i.e., genetic, reproductive, dietary, lifestyle and
     environmental. It both stimulates the division of breast cells
     (healthy as well as cancerous) and, especially in its 'bad' form,
     increases the risk of breast cancer. Thus, hormonal drugs such as
     tamoxifen that block the effects of estrogen on the breast were
     expected to reduce the risk of breast cancer recurring in women
     treated for breast cancer. (3)

     Tamoxifen acts as a weak estrogen by competing for estrogen
     receptors much as phyto-estrogens do. Like phyto-estrogens,
     tamoxifen has mild estrogenic properties but is considered an
     anti-estrogen since it inhibits the activity of regular estrogens.
     More accurately, tamoxifen is an estrogen-blocker. It fights
     breast cancer by competing with estrogen for space on estrogen
     receptors in the tumor tissue. Every tamoxifen molecule that hooks
     onto an estrogen receptor prevents an estrogen molecule from
     linking up at the same site. Without a steady supply of estrogen,
     cells in an estrogen-receptor-positive (ER+) tumor do not thrive
     and the tumor's ability to spread is reduced. (4)

     However, tamoxifen exhibited two conflicting characteristics. It
     could act either as an anti-estrogen or as an estrogen. Therefore,
     while tamoxifen is anti-estrogenic to the breast, it also acts as
     an estrogen to the uterus and, to a lesser extent, the heart,
     blood vessels and bone. So, although it initially showed the
     tendency to counter breast cancer recurrence, it would soon be
     revealed that it also promoted particularly aggressive uterine and
     liver cancers, caused fatal blood clots and interfered with many
     other functions.

     Doctors, however, were quick to jump on the tamoxifen bandwagon,
     turning a blind eye to its more injurious tendencies. Starting in
     the 1970's oncologists began using tamoxifen to treat women with
     cancer, often in combination with other drugs, radiation or
     surgery such as lumpectomy and mastectomy, with modest success.
     Like DES, tamoxifen's benefits were then extended for use as a
     preventive against osteoporosis and heart disease.

     Today, doctors are treating about one million American breast
     cancer patients with tamoxifen, about 20 per cent of them for more
     than five years. As studies published in the New England Journal
     of Medicine in 1989 and the Journal of the National Cancer
     Institute in 1992 showed, women with breast cancer who took
     tamoxifen reduced their chances of developing cancer in the other
     breast (contralateral cancer) by about 30 to 50 per cent. (3)
     These findings would later be challenged.

     Tamoxifen is now recommended for all pre-menopausal women with
     hormone-positive cancers, as well as for most postmenopausal women
     with breast cancer and/or a growing number of women with
     hormone-negative cancers. Tamoxifen is currently used by more
     women with breast cancer than any other drug. (6)

     Tamoxifen (brand name Nolvadex) is now the most widely prescribed
     cancer medication in the world. It generated revenues of US $265
     million in 1992. By 1995, worldwide sales of Nolvadex reached $400
     million. (7) And at AUD $90 for one month's supply, it doesn't
     come cheap (the Australian Pharmaceutical Benefits Scheme covers

     Tamoxifen was developed by UK-based Imperial Chemical Industries
     (ICI), one of the world's largest multinational chemical
     corporations. Zeneca, an ICI subsidiary, is responsible for
     manufacturing and marketing the hormone and is now the world's
     largest cancer-drug company.

     It is no surprise that ICI's profits come from playing both sides
     of the cancer industry. ICI's agrochemical division, which
     includes Zeneca, manufactures chlorinated and other industrial
     chemicals including herbicides. All are poisonous, and many are
     known endocrine-disrupters that have been incriminated as causes
     of breast cancer. ICI's profits swell by manufacturing chemicals
     that on the one hand cause breast cancer, and on the other hand
     reputedly cure breast cancer.

                        LIMITED BENEFITS OF TAMOXIFEN

     Tamoxifen 's benefits are determined by several factors: (8)

        * Postmenopausal women who are ER-positive (have a positive
          estrogen receptor status) get the most benefit.
        * For postmenopausal women who are ER-negative, the benefits
          appear to outweigh the risks.
        * For pre-menopausal women who are ER-positive, it's a tough
          call. Potential benefits are small.
        * Pre-menopausal women who are ER negative receive virtually no
        * Tamoxifen is more effective in women who have cancer in their
          lymph nodes than in those whose nodes are cancer-free.

     In 1992 the Lancet published a review of a number of studies in
     which a total of 30,000 breast cancer patients were randomly
     assigned either to take tamoxifen or not. The average patient in
     this collaborative study was followed up for between five and six
     years. Of the patients taking tamoxifen, 74.4 per cent survived,
     as compared with 70.9 per cent in the non-tamoxifen group - a less
     than impressive improvement.

     The report found that the group helped most consisted of
     post-menopausal women with ER-positive status. The study went on
     to report that pre-menopausal women who are ER-negative had
     absolutely no benefit from taking tamoxifen. (9)

     Despite tamoxifen's proven ability to reduce breast cancer
     recurrence in postmenopausal women, major studies have shown that
     tamoxifen reduces death from breast cancer only marginally. (10)
     The majority of women who take tamoxifen live no longer than women
     who do not take it. (11) Furthermore, some breast cancers learn
     how to use tamoxifen to stimulate their growth.

     The benefits of tamoxifen are limited. Virtually all women who
     take it become resistant within five years. (12) A recent
     randomized controlled study showed that tamoxifen reached its
     maximum protective effect on breast tissue with women who took it
     for five years. Taking it for five more years didn't offer any
     more protection, and may actually have caused more cancers. In
     other words, after a while the breast cells become resistant to
     tamoxifen and actually start to be fed by it. (13)

     This result surprised the researchers. According to Dr. Susan
     Love, author of Dr. Susan Love's Hormone Book: "This is a dramatic
     example of why you need good, long-term studies. If we had based
     all of our recommendations on the five-year data without doing
     further studies, we would have had women taking tamoxifen forever.
     So convinced were we that tamoxifen was a wonder drug that the
     only reason researchers did the later study at all was to prove it
     wrong. Luckily, we found out that we were wrong in time to prevent
     doing further damage. We have learned, not for the first time,
     that more isn't always better." (l4)

                            TAMOXIFEN'S DARK SIDE

     While the initial findings of tamoxifen's role in breast cancer
     treatment seemed so promising, as with so many of the synthetic
     hormone drugs, further research presented grave concerns for its
     widespread use. In fact, the MIMS Annual lists 25 adverse
     reactions to tamoxifen: some of l these can be fatal.

                             Menopausal Symptoms

     Tamoxifen often induces menopausal symptoms in menstruating women.
     About half of these women experience hot flushes. Fluid retention
     and weight I gain occur in about 25 per cent of l women and can be
     controlled by reducing the dose. Vaginal discharge and vaginal
     atrophy are additional symptoms. Some studies have also found l
     that pre-menopausal users are at risk of developing accelerated
     bone-mineral loss and osteoporosis.

     Menstrual irregularities also occur in pre-menopausal women.
     Amenorrhea (absence of the menstrual cycle) often results and can
     be permanent.

                                 Eye Damage

     According to a 1978 study in Cancer Treatment Reports and another
     published in Cancer in 1992, about six per cent of women taking
     even low-dose tamoxifen suffer damage to the retina and corneal
     opacities and decreased visual acuity. Irreversible corneal and
     retinal changes can occur in those taking 20 mg. of tamoxifen
     twice a day (twice the usual dose). These changes may have no
     immediate effect on visual acuity, but may predispose the eyes to
     later problems including cataracts.

                                 Blood Clots

     Tamoxifen irritates the walls of the veins, and inflammation (a
     natural healing response to irritation) follows. The constant
     irritation and inflammation weakens the veins, causing bleeding,
     clotting, thrombophlebitis and, in the worst cases, obstruction of
     the blood vessels serving the lungs, which can be deadly and can
     occur with little warning. The incidence of thrombophlebitis in
     women using oral contraceptives is generally regarded as
     significant (1 in 2,000); however, with tamoxifen it's 30 times

     Several studies, including one reported to the FDA's Oncological
     Drugs Advisory Committee by the National Surgical Adjuvant Breast
     and Bowel Project in 1991, showed that the risk of developing
     life-threatening blood clots increases about seven times in women
     taking tamoxifen. (6)

                           Psychological Symptoms

     Depression has been reported as a potential side-effect of
     tamoxifen in 30 per cent of women. Cases have been reported of an
     inability to concentrate.

     It is important that patients observe their moods and mental
     states. If it is suspected at tamoxifen is causing depression or
     lack of concentration, it is suggested that a period of tamoxifen
     avoidance be considered.

                               Other Symptoms

     Tamoxifen can trigger asthma attacks in some sensitive patients.

     Changes to the vocal cords resulting in impairment of singing and
     speaking abilities are occasionally caused by tamoxifen.

                           CARCINOGENENIC EFFECTS

     It wasn't long before laboratory studies showed that tamoxifen
     acted as a carcinogen. It has been found that tamoxifen binds
     tightly and irreversibly to DNA, the genetic blueprint of a cell,
     causing a cancerous mutation to take place. Even Australia's
     conservative National Health and Medical Research Council (NHMRC)
     warned that no amount of tamoxifen is safe when it comes to
     carcinogenic effects.

     In California there is a law called "Proposition 65" that requires
     the state to publish and maintain a list of all known carcinogens.
     In May 1995, the state's Carcinogen Identification Committee voted
     unanimously to add tamoxifen to its list.

     Following suit, in 1996 the World Health Organization formally
     designated tamoxifen a human carcinogen, grouping it with 70 other
     chemicals - about one quarter of them pharmaceuticals - that have
     received this dubious distinction.

                       Liver Cancer and Liver Disease

     Tamoxifen is toxic to the liver, and there have been reports of
     acute hepatitis in patients treated with tamoxifen. Liver damage
     has occurred in every animal given tamoxifen. According to Gary
     Williams, medical director of the American Heart Foundation,
     tamoxifen has been shown in animal studies to be a "rip-roaring"
     liver carcinogen, inducing highly aggressive cancers in about 12
     per cent of rats. (7)

     The latest human studies show a six-fold increase in liver cancer
     among women taking tamoxifen for more than two years." Liver
     failure and tamoxifen-induced hepatitis, although rare, have been
     reported. Even Zeneca admits that tamoxifen is a liver carcinogen
     - while nevertheless aggressively promoting its use.

                                                Uterine (Endometrial)

     As early as 1967, ICI scientists noted that "tamoxifen persists
     for some days in the uterus". In rats, a tamoxifen metabolite (a
     breakdown compound almost similar in structure to the original)
     was found to influence the uterus to be more receptive to
     estrogen. (The more estrogen, the greater the chance of unnatural
     cell-division leading to cancer.) ICI also reported liver
     carcino-genicity of tamoxifen as well as both ovarian and
     testicular tumors in mice in its description of the drug in the
     standard Physicians Desk Reference.

     Uterine growths such as polyps, tumors, endometrial thickenings
     and cancers occur in a significant number of women taking
     tamoxifen. One study detected abnormal endometrial cells in
     subjects the day after the first tablet was taken. (9)
     Pre-cancerous uterine and endometrial changes were seen in 10 per
     cent of the women taking tamoxifen in a recent study. The higher
     the dose of tamoxifen and the longer it is taken, the greater the
     risk of changes. Women taking the standard dose of 20 mg. for two
     years run a risk of uterine cancer that is 2 to 3 times greater
     than normal. After five years, the risk is 6 to 8 times greater.

     In February 1996 a review by the International Agency for Research
     on Cancer, composed of scientists from various countries,
     definitively concluded that "there is sufficient evidence to
     regard tamoxifen as a human carcinogen that increases a woman's
     risk of developing cancer of the endometrium, the inner lining of
     the uterus" (21)

     A large Swedish study linking tamoxifen to uterine cancer forced
     Zeneca to send letters in April 1994 to 380,000 physicians across
     the USA, in defense of the drug. The Swedish researchers had
     studied 1,371 breast cancer patients who took 40 mg. per day for
     two to five years and found that there was a six-fold increase in
     uterine cancer among those patients who took tamoxifen when
     compared to 1,327 who did not. A second study involving patients
     who took 20 mg. per day (the recommended dose) also showed a
     marked increase in uterine cancers compared with the control
     group. (22)

     When the news came out that breast cancer patients who took
     tamoxifen for five years or longer (the same regimen that seems to
     prevent recurrence) might have tripled their risk of uterine
     cancer, British cancer researcher Richard Peto, head of the cancer
     research unit at Oxford University, sought to dismiss it. If
     caught early, he said, endometrial cancer seldom kills, so "it's
     no big deal". That statement infuriated critics who noted that the
     treatment for uterine cancer is hysterectomy. Dr. Adriane
     Fugh-Berman, a leading women's health activist, angrily responded:
     "To some of us, it is a big deal to lose your uterus."

     Shortly after Peto's flip dismissal of uterine cancers,
     researchers at the M. D. Anderson Cancer Center at Houston and at
     Yale University School of Medicine discovered that breast cancer
     patients who develop uterine cancer while using tamoxifen are
     likely to have a fast-moving, lethal form of the disease. (23)

     It should be noted that tamoxifen has also been associated with
     gastrointestinal cancers.

                                Breast Cancer

     The premise for taking tamoxifen is its supposed role in
     protecting breast cancer patients from recurrence of the cancer.
     It was further postulated that it prevented breast cancer from
     occurring in the opposite breast (contralateral).

     However, disturbing findings continue to surface, challenging
     tamoxifen's effectiveness. In 1992 the New England Journal of
     Medicine showed that tamoxifen may reduce the incidence of
     contralateral cancer, but this was demonstrated only in
     pre-menopausal women and only in three out of eight trials. In
     another 1992 study, reported in Octa Oncologica, it was shown that
     tamoxifen not only failed to reduce contralateral cancers in
     pre-menopausal women, but it actually increased their incidence.

     The irony of tamoxifen is that, while widely publicized as the
     leading treatment against the recurrence of breast cancer, it is a
     known and listed carcinogenic substance.

                       Heart Disease and Osteoporosis

     Another promise of tamoxifen was its supposed protective benefits
     for the heart and bones. It was theorized that its estrogenic
     properties would help reduce heart disease and osteoporosis in
     women, but once again the theory crumbled under the weight of hard

     Several trials with tamoxifen failed to show that it has any
     effect on bone density and thus on prevention of osteoporosis. In
     three other trials, bone density increased slightly in lower
     spinal vertebrae but not in longer bones or hip bones which are
     particularly susceptible to fractures and potentially fatal

     Initial data seemed to indicate that it decreased the incidence of
     heart attacks, but they have been disproved by more recent
     studies. According to Dr. Susan Love: "It doesn't seem to have a
     bad effect on lipids, but that's a far cry from preventing heart

     A detailed review of the drug's alleged protective cardiovascular
     effects prompted the British National Heart, Lung and Blood
     Institute, a once strong proponent of tamoxifen, to withdraw its
     support because the evidence of benefit proved so inadequate. (25)

     According to the January 1996 issue of The Network News, it was
     reported at a closed-door meeting of the National Cancer Institute
     that tamoxifen failed to prevent heart disease in breast cancer


     Based far more on wishful thinking than on science, the U.S.
     National Cancer Institute (NCI) leaped to the conclusion that
     tamoxifen's anti-estrogenic effects in relation to breast cancer
     treatment meant that the drug would prevent breast cancer from
     developing in healthy women.

     Disregarding all the research implicating tamoxifen with serious
     and potentially fatal side-effects, the NCI launched a US$60
     million breast cancer prevention trial in April 1992, aiming to
     recruit 16,000 healthy women in the United States, Europe, Canada,
     Australia and New Zealand. Still ongoing, the trial now involves
     13,000 healthy women over the age of 35 who are considered at high
     risk. Australia has recruited 1,350 women, with a target of 2,500.
     For five years, half the women receive tamoxifen and half receive
     a placebo. The drug is supplied free of charge by manufacturer

     Dr. Samuel Epstein, Professor Environmental Medicine at the
     University of Illinois School of Public Health and author of The
     Breast Cancer Prevention Program, raises serious concerns.
     "Unfortunately, this misguided and dangerous approach to
     prevention stems from the entrenched fixation of the NCI on the
     use of chemical drugs to prevent cancer which may have been
     induced by chemical pollutants, medical technology (such as
     radiation from X-rays) and carcinogenic/estrogenic drugs in the
     first place. Instead of attempting to reduce the carcinogenic
     chemical burden under which we struggle to maintain our health,
     the NCI believes that the solution is to add more chemicals to the

     Dr. Susan Love concurs: "It is a sad state of affairs when we have
     to add yet more chemicals to counteract the effects of other

     This attitude extends to the way the NCI treats the women in the
     trial. They are given no guidance on alternative protective
     measures such as increasing exercise, maintaining a healthy
     weight, eating a protective diet and avoiding exposure to
     environmental carcinogens; nor are they being fully informed about
     the serious risks of tamoxifen.

     Dr. Lynette Dumble, Senior Research Fellow in History and
     Philosophy of Science at the University of Melbourne, believes
     that the global trial to prevent breast cancer with tamoxifen is a
     modern and very large chapter of "medical imperialism". Back in
     October 1994 she commented on ABC TV's Quantum science program
     that the tamoxifen trial was the medical equivalent of mutilating
     surgery which prevents a woman from developing breast cancer by
     cutting off both her breasts.

     Dr. Dumble sees women as vulnerable guinea pigs for the trial, and
     questions both the breast cancer risk of healthy women
     volunteering for the trial (how can you tell whether fate or
     tamoxifen prevents a woman from developing breast cancer?) and the
     terms of the trial's positives and negatives (if a woman dies of
     tamoxifen-related endometrial or liver cancer, does this count as
     a tamoxifen success in preventing breast cancer?).

     It seems absurd, but why would the powers-that-be continue to
     promote a trial that promises to substitute one cancer for another
     in otherwise healthy women? Once again, healthy women are targeted
     as the guinea pigs for a drug treatment that has already been
     proven to be a cause of a variety of cancers including breast
     cancer. In the case of tamoxifen, medical research has once again
     taken a back seat to profits. It is the population that is at
     risk. The cancer establishment would certainly be eager to prove a
     tamoxifen-prevention role, since it would then open up another
     huge, billion-dollar market.

                          ALTERNATIVES TO TAMOXIFEN

     While the cancer establishment continues to invest vast amounts of
     money into research, manufacturing and trialling of harmful drugs
     for the prevention and hopeful cure of breast cancer, there are
     safer and more effective options that already exist.

     Estriol, one of the estrogens produced by the ovaries, is
     considered a safe estrogen in that it has been shown to inhibit
     breast cancer. Dr. Henry Lemon and his colleagues conducted a
     study in women who already had breast cancer that had spread to
     other areas of the body. One group was given Estriol and another
     not. At the end of the study, 37 per cent of those women who
     received estriol had either a remission or an arrest of their
     cancer. Might not estriol, a natural, safe hormone with almost no
     side-effects, be able to accomplish what tamoxifen does but
     without the toxic side-effects?

     There is also convincing evidence that natural progesterone has an
     important role in breast cancer treatment and prevention. A study
     conducted in 1981 at Johns Hopkins University revealed that when a
     group with a low progesterone level was compared with a
     normal-level progesterone group, it was found that the occurrence
     of breast cancer was 5.4 times greater in the women in the low
     progesterone group. That is, the incidence of breast cancer in the
     low progesterone group was over 80 per cent greater than in the
     normal progesterone group. When the researchers looked at the low
     progesterone group for all types of cancer, they found that these
     women experienced a tenfold increase in all malignant cancers,
     compared to the normal group.

     In a 1995 study published in the Journal of Fertility and
     Sterility, researchers found that women using a topical
     progesterone cream had dramatically reduced breast cell
     multiplication rates compared to women using either a placebo or
     estrogen. This exciting study demonstrated that natural
     progesterone creams impressively decreased breast cell
     proliferation rates. (27)

     Lifestyle factors also play a significant role. In a prospective
     study of 25,624 Norwegian women aged 20 to 54, after an average of
     14 years of follow-up the investigators found strong evidence that
     everyday exercise, both at work and at leisure, reduced the breast
     cancer risk. Women who exercised at least four hours a week during
     leisure time were found to have a 37 per cent reduction in risk of
     breast cancer, compared with sedentary women. The study found that
     the more time spent exercising, the lower the breast cancer risk.

     As Dr. John Lee pointed out in his best-selling book, What Doctors
     May Not Tell You About Menopause: "Herbs and food contain
     phyto-estrogens. Their benefit parallels that of tamoxifen
     (without the adverse side-effects) in that phyto-estrogens occupy
     estrogen receptors and are less estrogenic than those made by the
     body. Since it is now known that reducing caloric intake reduces
     estrogen levels, and recent studies find 46 per cent less breast
     cancer among women consuming more fruit and vegetables, it would
     seem that women interested in preventing breast cancer could make
     modest changes in diet and derive better and certainly safer
     results." (29)

     History continues to repeat itself. Time and time again women have
     been reassured that the wonder drugs or treatments offered them
     would be their salvation, only to discover they were exposed to
     harmful carcinogenic and mutagenic chemicals.

     In addition to the DES debacle, the disasters of thalidomide,
     silicone breast implants, estrogen replacement therapy and now
     tamoxifen (to name just a few) continue to demonstrate how readily
     women's lives have been sacrificed in the pursuit of profits. The
     warnings have been drowned out by the glossy advertising campaigns
     and the reassurances of "medical experts".

     There are solutions to the breast cancer epidemic. However, they
     will be found more by altering lifestyle, dietary and stress
     factors, and reducing or eliminating exposure to the many known
     toxic, carcinogenic chemicals that are polluting the environment,
     than by some miraculous drug discovery. It is also up to women not
     only to continue to become fully educated about safe health
     options but to demand them from health providers. Too many women
     have already been maimed and sacrificed to unproven and unsafe
     drug treatments.

     It is widely believed that today's drugs are tomorrow's poisons.
     In the case of tamoxifen, tomorrow has already arrived.

                                 End notes:

  1. Weed, Susan S., Breast Cancer? Breast Health!, Ash Tree Publishing,
     Woodstock, New York, 1996, page 203
  2. Batt, Sharon, Patient No More: The Politics of Breast Cancer,
     Press, Melbourne, Australia, 1994, page 118
  3. Epstein MD, Samuel S.; Steinman, David; LeVert, Suzanne; The Breast
     Cancer Prevention Program, Macmillan, New York, 1997, page 145
  4. Rinzler, Carol Ann, Estrogen and Breast Cancer, Hunter House,
     California, 1996, pages 148 - 149
  5. Epstein, ibid., page 146
  6. Weed, ibid., page 201
  7. Clorfene-Casten, Liane, Breast Cancer: Poisons, Profits and
     Common Courage Press, Maine, USA, 1996, page 93
  8. Austin ND, Steve; Hitchcock, Cathy; Breast Cancer: What You Should
     (But May Not Be Told) About Prevention, Diagnosis and Treatment,
     Publishing, Rocklion, California, 1994, page 102
  9. Early Breast Cancer Trials Collaborative Group, "Systemic treatment
     early breast cancer by hormonal, cytotoxic, or immune therapy." The
     Lancet (1992) 339, pages 1 - 15, 71 - 85
 10. De Gregorio, M. and Wibe, V., Tamoxifen and Breast Cancer, Yale
     University, USA, 1994
 11. Batt, ibid., page 125
 12. De Gregorio and Wibe, op. cit.
 13. Love MD, Susan, Dr. Susan Love's Hormone Book, Random House, New
     1997, page 264
 14. Ibid., pages 264 - 265
 15. Weed, ibid., page 204
 16. Epstein, ibid., page 149
 17. Ibid.
 18. Weed, ibid., page 205
 19. Adler, T., "Study reaffirms tamoxifen's dark side", Science News,
     4, 1994, page 356
 20. "Studies spark tamoxifen controversy", Science News, February 26,
     page 133
 21. Nesmith, Jeff, "Breast Cancer Drug Increases Risk:, The Atlanta
     / The Atlanta Constitution, February 22, 1996
 22. Clorfene-Casten, ibid., page 89
 23. Rinzler, ibid., page 152
 24. Epstein, ibid., page 146
 25. Ibid., page 148
 26. Northrup MD, Christiane, Women's Bodies, Women's Wisdom, Bantam
     New York, 1996, page 158
 27. Sellman, Sherrill, Hormone Heresy: What Women MUST Know About Their
     Hormones, GetWell International, USA, 1997, pages 107 - 108
 28. Thune MD, Inger, et al., New England Journal of Medicine, May 1,
 29. Lee MD, John R., What Doctors May Not Tell You About Menopause,
     Books, New York, 1996, page 220

We invite you to take a look at our Album.

  ( Very informational, good tips, Molers pictures, art work and much

We invite you to take a look at our Album.

  ( Very informational, good tips, Molers pictures, art work and much

----- Original Message -----
From: jo anne king <>
To: <>
Sent: Sunday, May 28, 2000 1:15 PM

> I was diagnosed with breast cancer 1 year ago.  Had a lumpectomy and
> found no lymphnode involvement. Since taking tamoxifen I have developed
> much pain in arms, legs and pre-existing arthritus is much worse.  Am
> also  intereste in any link with tamoxifen side effects.
> ------------------------------------------------------------------------
> This is an automatically-generated notice.  If you'd like to be removed
> from the mailing list, please visit the Medicine-On-Line Discussion Forum
> at <>, or send an email message to:
> with the subject line blank and the body of the message containing the
> unsubscribe mol-cancer your-email-address
> where the phrase your-email-address is replaced with your actual email
> address.
> ------------------------------------------------------------------------

This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <>, or send an email message to:
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email